Recommendations for prevention and control of influenza in children, 2018-2019

COMMITTEE ON INFECTIOUS DISEASES

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

The authors of this statement update the recommendations of the American Academy of Pediatrics for the routine use of infuenza vaccine and antiviral medications in the prevention and treatment of infuenza in children. Highlights for the upcoming 2018-2019 season include the following: 1. Annual infuenza immunization is recommended for everyone 6 months and older, including children and adolescents. 2. The American Academy of Pediatrics recommends an inactivated infuenza vaccine (IIV), trivalent or quadrivalent, as the primary choice for infuenza vaccination in children because the effectiveness of a live attenuated infuenza vaccine against infuenza A(H1N1) was inferior during past infuenza seasons and is unknown for this upcoming season. 3. A live attenuated infuenza vaccine may be used for children who would not otherwise receive an infuenza vaccine (eg, refusal of an IIV) and for whom it is appropriate because of age (2 years of age and older) and health status (ie, healthy and without any underlying chronic medical condition). 4. All 2018-2019 seasonal infuenza vaccines contain an infuenza A(H1N1) vaccine strain similar to that included in the 2017-2018 seasonal vaccines. In contrast, the infuenza A(H3N2) and infuenza B (Victoria lineage) vaccine strains included in the 2018-2019 trivalent and quadrivalent vaccines differ from those in the 2017-2018 seasonal vaccines. a. Trivalent vaccines contain an infuenza A(Michigan/45/2015[H1N1]) pdm09-like virus, an infuenza A(Singapore/INFIMH-16-0019/2016[H3N2])- like virus (updated), and an infuenza B (Colorado/60/2017)-like virus (B/Victoria lineage; updated). b. Quadrivalent vaccines contain an additional B virus (Phuket/3073/2013- like virus; B/Yamagata lineage). 5. All children with egg allergy of any severity can receive an infuenza vaccine without any additional precautions beyond those recommended for all vaccines. 6. Pregnant women may receive an infuenza vaccine (IIV only) at any time during pregnancy to protect themselves as well as their infants, who beneft from the transplacental transfer of antibodies. Postpartum women who did not receive vaccination during pregnancy should be encouraged to receive an infuenza vaccine before discharge from the hospital. Infuenza vaccination during breastfeeding is safe for mothers and their infants. 7. The vaccination of health care workers is a crucial step in preventing infuenza and reducing health care-associated infuenza infections because health care personnel often care for individuals at high risk for infuenza-related complications. 8. Pediatricians should attempt to promptly identify their patients who are suspected of having an infuenza infection for timely initiation of antiviral treatment when indicated and on the basis of shared decision-making between each pediatrician and child caregiver to reduce morbidity and mortality. Although best results are seen when a child is treated within 48 hours of symptom onset, antiviral therapy should still be considered beyond 48 hours of symptom onset in children with severe disease or those at high risk of complications (see Table 2 in the full policy statement).

Original languageEnglish (US)
Article numbere20182367
JournalPediatrics
Volume142
Issue number4
DOIs
StatePublished - Oct 1 2018

Fingerprint

Human Influenza
Vaccines
Inactivated Vaccines
Vaccination
Antiviral Agents
Cercopithecine Herpesvirus 1
Attenuated Vaccines
Victoria
Egg Hypersensitivity
Time-to-Pregnancy
H3N2 Subtype Influenza A Virus
Pediatrics
Viruses
Delivery of Health Care
Singapore
Cross Infection
Breast Feeding
Health Personnel
Postpartum Period
Caregivers

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Recommendations for prevention and control of influenza in children, 2018-2019. / COMMITTEE ON INFECTIOUS DISEASES.

In: Pediatrics, Vol. 142, No. 4, e20182367, 01.10.2018.

Research output: Contribution to journalReview article

COMMITTEE ON INFECTIOUS DISEASES. / Recommendations for prevention and control of influenza in children, 2018-2019. In: Pediatrics. 2018 ; Vol. 142, No. 4.
@article{50bcd633be284379b2e05b8154ff747d,
title = "Recommendations for prevention and control of influenza in children, 2018-2019",
abstract = "The authors of this statement update the recommendations of the American Academy of Pediatrics for the routine use of infuenza vaccine and antiviral medications in the prevention and treatment of infuenza in children. Highlights for the upcoming 2018-2019 season include the following: 1. Annual infuenza immunization is recommended for everyone 6 months and older, including children and adolescents. 2. The American Academy of Pediatrics recommends an inactivated infuenza vaccine (IIV), trivalent or quadrivalent, as the primary choice for infuenza vaccination in children because the effectiveness of a live attenuated infuenza vaccine against infuenza A(H1N1) was inferior during past infuenza seasons and is unknown for this upcoming season. 3. A live attenuated infuenza vaccine may be used for children who would not otherwise receive an infuenza vaccine (eg, refusal of an IIV) and for whom it is appropriate because of age (2 years of age and older) and health status (ie, healthy and without any underlying chronic medical condition). 4. All 2018-2019 seasonal infuenza vaccines contain an infuenza A(H1N1) vaccine strain similar to that included in the 2017-2018 seasonal vaccines. In contrast, the infuenza A(H3N2) and infuenza B (Victoria lineage) vaccine strains included in the 2018-2019 trivalent and quadrivalent vaccines differ from those in the 2017-2018 seasonal vaccines. a. Trivalent vaccines contain an infuenza A(Michigan/45/2015[H1N1]) pdm09-like virus, an infuenza A(Singapore/INFIMH-16-0019/2016[H3N2])- like virus (updated), and an infuenza B (Colorado/60/2017)-like virus (B/Victoria lineage; updated). b. Quadrivalent vaccines contain an additional B virus (Phuket/3073/2013- like virus; B/Yamagata lineage). 5. All children with egg allergy of any severity can receive an infuenza vaccine without any additional precautions beyond those recommended for all vaccines. 6. Pregnant women may receive an infuenza vaccine (IIV only) at any time during pregnancy to protect themselves as well as their infants, who beneft from the transplacental transfer of antibodies. Postpartum women who did not receive vaccination during pregnancy should be encouraged to receive an infuenza vaccine before discharge from the hospital. Infuenza vaccination during breastfeeding is safe for mothers and their infants. 7. The vaccination of health care workers is a crucial step in preventing infuenza and reducing health care-associated infuenza infections because health care personnel often care for individuals at high risk for infuenza-related complications. 8. Pediatricians should attempt to promptly identify their patients who are suspected of having an infuenza infection for timely initiation of antiviral treatment when indicated and on the basis of shared decision-making between each pediatrician and child caregiver to reduce morbidity and mortality. Although best results are seen when a child is treated within 48 hours of symptom onset, antiviral therapy should still be considered beyond 48 hours of symptom onset in children with severe disease or those at high risk of complications (see Table 2 in the full policy statement).",
author = "{COMMITTEE ON INFECTIOUS DISEASES} and Maldonado, {Yvonne A.} and Zaoutis, {Theoklis E.} and Ritu Banerjee and Barnett, {Elizabeth D.} and Campbell, {James D.} and Gerber, {Jeffrey S.} and Kourtis, {Athena P.} and Ruth Lynfield and Munoz, {Flor M.} and Dawn Nolt and Nyquist, {Ann Christine} and O'Leary, {Sean T.} and Sawyer, {Mark H.} and Steinbach, {William J.} and Tan, {Tina Q.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1542/peds.2018-2367",
language = "English (US)",
volume = "142",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "4",

}

TY - JOUR

T1 - Recommendations for prevention and control of influenza in children, 2018-2019

AU - COMMITTEE ON INFECTIOUS DISEASES

AU - Maldonado, Yvonne A.

AU - Zaoutis, Theoklis E.

AU - Banerjee, Ritu

AU - Barnett, Elizabeth D.

AU - Campbell, James D.

AU - Gerber, Jeffrey S.

AU - Kourtis, Athena P.

AU - Lynfield, Ruth

AU - Munoz, Flor M.

AU - Nolt, Dawn

AU - Nyquist, Ann Christine

AU - O'Leary, Sean T.

AU - Sawyer, Mark H.

AU - Steinbach, William J.

AU - Tan, Tina Q.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - The authors of this statement update the recommendations of the American Academy of Pediatrics for the routine use of infuenza vaccine and antiviral medications in the prevention and treatment of infuenza in children. Highlights for the upcoming 2018-2019 season include the following: 1. Annual infuenza immunization is recommended for everyone 6 months and older, including children and adolescents. 2. The American Academy of Pediatrics recommends an inactivated infuenza vaccine (IIV), trivalent or quadrivalent, as the primary choice for infuenza vaccination in children because the effectiveness of a live attenuated infuenza vaccine against infuenza A(H1N1) was inferior during past infuenza seasons and is unknown for this upcoming season. 3. A live attenuated infuenza vaccine may be used for children who would not otherwise receive an infuenza vaccine (eg, refusal of an IIV) and for whom it is appropriate because of age (2 years of age and older) and health status (ie, healthy and without any underlying chronic medical condition). 4. All 2018-2019 seasonal infuenza vaccines contain an infuenza A(H1N1) vaccine strain similar to that included in the 2017-2018 seasonal vaccines. In contrast, the infuenza A(H3N2) and infuenza B (Victoria lineage) vaccine strains included in the 2018-2019 trivalent and quadrivalent vaccines differ from those in the 2017-2018 seasonal vaccines. a. Trivalent vaccines contain an infuenza A(Michigan/45/2015[H1N1]) pdm09-like virus, an infuenza A(Singapore/INFIMH-16-0019/2016[H3N2])- like virus (updated), and an infuenza B (Colorado/60/2017)-like virus (B/Victoria lineage; updated). b. Quadrivalent vaccines contain an additional B virus (Phuket/3073/2013- like virus; B/Yamagata lineage). 5. All children with egg allergy of any severity can receive an infuenza vaccine without any additional precautions beyond those recommended for all vaccines. 6. Pregnant women may receive an infuenza vaccine (IIV only) at any time during pregnancy to protect themselves as well as their infants, who beneft from the transplacental transfer of antibodies. Postpartum women who did not receive vaccination during pregnancy should be encouraged to receive an infuenza vaccine before discharge from the hospital. Infuenza vaccination during breastfeeding is safe for mothers and their infants. 7. The vaccination of health care workers is a crucial step in preventing infuenza and reducing health care-associated infuenza infections because health care personnel often care for individuals at high risk for infuenza-related complications. 8. Pediatricians should attempt to promptly identify their patients who are suspected of having an infuenza infection for timely initiation of antiviral treatment when indicated and on the basis of shared decision-making between each pediatrician and child caregiver to reduce morbidity and mortality. Although best results are seen when a child is treated within 48 hours of symptom onset, antiviral therapy should still be considered beyond 48 hours of symptom onset in children with severe disease or those at high risk of complications (see Table 2 in the full policy statement).

AB - The authors of this statement update the recommendations of the American Academy of Pediatrics for the routine use of infuenza vaccine and antiviral medications in the prevention and treatment of infuenza in children. Highlights for the upcoming 2018-2019 season include the following: 1. Annual infuenza immunization is recommended for everyone 6 months and older, including children and adolescents. 2. The American Academy of Pediatrics recommends an inactivated infuenza vaccine (IIV), trivalent or quadrivalent, as the primary choice for infuenza vaccination in children because the effectiveness of a live attenuated infuenza vaccine against infuenza A(H1N1) was inferior during past infuenza seasons and is unknown for this upcoming season. 3. A live attenuated infuenza vaccine may be used for children who would not otherwise receive an infuenza vaccine (eg, refusal of an IIV) and for whom it is appropriate because of age (2 years of age and older) and health status (ie, healthy and without any underlying chronic medical condition). 4. All 2018-2019 seasonal infuenza vaccines contain an infuenza A(H1N1) vaccine strain similar to that included in the 2017-2018 seasonal vaccines. In contrast, the infuenza A(H3N2) and infuenza B (Victoria lineage) vaccine strains included in the 2018-2019 trivalent and quadrivalent vaccines differ from those in the 2017-2018 seasonal vaccines. a. Trivalent vaccines contain an infuenza A(Michigan/45/2015[H1N1]) pdm09-like virus, an infuenza A(Singapore/INFIMH-16-0019/2016[H3N2])- like virus (updated), and an infuenza B (Colorado/60/2017)-like virus (B/Victoria lineage; updated). b. Quadrivalent vaccines contain an additional B virus (Phuket/3073/2013- like virus; B/Yamagata lineage). 5. All children with egg allergy of any severity can receive an infuenza vaccine without any additional precautions beyond those recommended for all vaccines. 6. Pregnant women may receive an infuenza vaccine (IIV only) at any time during pregnancy to protect themselves as well as their infants, who beneft from the transplacental transfer of antibodies. Postpartum women who did not receive vaccination during pregnancy should be encouraged to receive an infuenza vaccine before discharge from the hospital. Infuenza vaccination during breastfeeding is safe for mothers and their infants. 7. The vaccination of health care workers is a crucial step in preventing infuenza and reducing health care-associated infuenza infections because health care personnel often care for individuals at high risk for infuenza-related complications. 8. Pediatricians should attempt to promptly identify their patients who are suspected of having an infuenza infection for timely initiation of antiviral treatment when indicated and on the basis of shared decision-making between each pediatrician and child caregiver to reduce morbidity and mortality. Although best results are seen when a child is treated within 48 hours of symptom onset, antiviral therapy should still be considered beyond 48 hours of symptom onset in children with severe disease or those at high risk of complications (see Table 2 in the full policy statement).

UR - http://www.scopus.com/inward/record.url?scp=85054340273&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054340273&partnerID=8YFLogxK

U2 - 10.1542/peds.2018-2367

DO - 10.1542/peds.2018-2367

M3 - Review article

VL - 142

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4

M1 - e20182367

ER -